Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

The role and therapeutic targeting of IL-6 in rheumatoid arthritis

(2017) Masashi Narazaki et al.   Expert Review of Clinical Immunology

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis

(2016) Rayford R. June et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan

(2016) Tsuneyo Mimori et al.   Modern Rheumatology

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)

(2014) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab

(2014) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis

(2014) Ryuji Koike et al.   Modern Rheumatology

Recent trends in use of nonbiologic DMARDs and evaluation of their continuation rates in single and dual combination therapies in rheumatoid arthritis patients in Japan

(2014) Michihiro Ogasawara et al.   Modern Rheumatology